William Keane, Vice President of Strategic Initiatives, Tevogen Bio
Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives
May 16, 2024 14:00 ET | Tevogen Bio Inc
Former police chief & FBI National Academy graduate, William Keane, to work with functional leads, ensure policies, procure Tevogen’s lab space.
Traws Pharma blue.png
Traws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update
May 16, 2024 09:29 ET | Traws Pharma, Inc.
Traws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update
AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 16, 2024 07:30 ET | AIM ImmunoTech Inc.
Continued execution across Ampligen® clinical development programs and growing body of positive data in multiple high-value indications Company to host conference call and webcast today, May...
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
May 16, 2024 06:00 ET | Arvinas Inc.
– After six months of additional follow-up, clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), and safety profile of vepdegestrant in...
NOVARTIS logo.jpg
Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash
May 16, 2024 05:27 ET | Novartis Pharma AG
Novartis secured 79.6 percent acceptance by MorphoSys shareholders during the initial acceptance period, reaching the minimum 65% acceptance thresholdSettlement of the shares tendered during the...
Oncocyte Reports First Quarter 2024 Financial Results
May 15, 2024 16:05 ET | OncoCyte Corporation
NOVARTIS logo.jpg
Novartis highlights pioneering innovation in CML with data from Scemblix® Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA
May 15, 2024 10:00 ET | Novartis Pharma AG
Primary results of the Scemblix® ASC4FIRST pivotal Phase III study in first-line Ph+ CML-CP supporting third US FDA Breakthrough Therapy designation, to be detailed in the ASCO Press Program and the...
CARGO Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024 16:05 ET | Cargo Therapeutics, Inc.
CARGO Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Saladax Biomedical, Inc. 5-FU Fact Sheet
Health Canada Approves Saladax’s 5-Fluorouracil Chemotherapy Therapeutic Drug Monitoring (TDM) Test
May 14, 2024 10:00 ET | Saladax Biomedical, Inc.
Bethlehem, PA, May 14, 2024 (GLOBE NEWSWIRE) -- Saladax Biomedical, Inc. (Saladax) is pleased to announce that Health Canada has approved Saladax’s 5-Fluorouracil (My5-FU) Assay for sale in Canada...
Kymera-Logo-RGB-Denim+Marigold - High Res.png
Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
May 14, 2024 10:00 ET | Kymera Therapeutics, Inc.
Abstract released today highlights safety, pharmacodynamic and clinical response data collected through February 6, 2024 cut-off date Updated data to be presented at the European Hematology...